Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Pulsatile Insulin Infusion in Diabetes
NCT04030091Phase 4Completed
- Sponsor
- Sciema
- Start
- Sep 2019
- Primary completion
- Oct 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of Humulin R + Kanglaite Injection in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Sciema. Primary endpoint: Endothelial function at 1 hour. Started Sep 2019; status: completed.
02
Drugs
Humulin R + Kanglaite Injection
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04030091.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04030091.